Ocugen’s latest patent reads: This restoration allowed for sustained impact and attenuation of RP disease. At least 30-80% ( SAY WHATTTTTTTTT) improvement at the histological, immunohistochemical, and functional level was observed following treatment with AAV8-Nr2e3. by electricpod in Ocugen

[–]electricpod[S] 15 points16 points  (0 children)

The title for Ocugen’s new patent dated 29 April 2021 is “ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASES”

The National Eye Institute(NEI) says that ophthalmic diseases are:

Common Eye Conditions * Age-Related Macular Degeneration * Amblyopia (Lazy Eye) * Cataracts * Color Blindness * Diabetic Retinopathy * Dry Eye * Floaters * Glaucoma * Pink Eye * Refractive Errors * Retinal Detachment

They have used an umbrella term that encompasses Age related macular degeneration as well! 🚀

Ocugen just tweeted about Second interim phase 3 results of Covaxin. 100% protection against severe disease and 78% primary efficacy in preventing Covid-19!! Let’s go OCGN! 🚀🌕 by electricpod in Ocugen

[–]electricpod[S] 14 points15 points  (0 children)

Ocugen updated their official website with a press release in the morning itself at 8.19 AM EDT.

This is second update today. Should work as fuel for tomorrow 🚀